Energy has an architecture. SS-31 binds the mitochondrial membrane.
A compounded SS-31 prescription centered on inner mitochondrial membrane and cardiolipin biology.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
About 10 minutes. No charge unless your clinician approves.
Energy starts with structure.
Mitochondria are usually discussed as if energy production were only a chemistry problem: more substrate in, more ATP out. But the machinery doing that work has to be physically organized before the chemistry can happen efficiently.
SS-31 is interesting because it goes after the architecture.
Elamipretide, the clinical-development name for SS-31, localizes to the inner mitochondrial membrane and binds cardiolipin, a lipid that helps organize that membrane and the energy-producing machinery embedded inside it.1 The molecule is not trying to add more fuel or broadly stimulate the cell. Its target is the structure that keeps the existing machinery arranged where it belongs.
That is a much more specific proposition than “more energy.” The cardiolipin mechanism is well defined even though mechanism alone cannot predict what a compounded prescription will do for an individual patient.
SS-31 binds cardiolipin in the inner mitochondrial membrane, giving it a defined structural target. CoQ10 participates in electron transport within the same energy-producing system, while SS-31 is studied for its relationship with the membrane that organizes that system.
- FDA, FORZINITY (elamipretide) Prescribing Information, initial US approval September 2025.FDA
For the person who already handled the obvious levers.
The Inputs Are Already Good
Sleep, training, nutrition, hormones, and labs are not neglected. You are interested in the machinery underneath those inputs because adding another basic habit is not the question anymore.
Your Margin Got Smaller
The routine still works, but the distance between normal output and being spent has narrowed. You are looking at capacity as a cellular systems question, not a motivation problem.
The Informed Mitochondrial Reader
You already know elamipretide has a real pharmaceutical history and a specific cardiolipin mechanism. You want the evidence, the limits, and the medical relevance separated cleanly rather than blended into a longevity claim.
Elamipretide is FDA-approved as FORZINITY to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. The preparation offered here is compounded for a different purpose, is not FORZINITY, and is not a substitute for the approved product. A licensed provider determines candidacy from your full Assessment.
This might not be the right fit if:
- You have a known serious hypersensitivity to elamipretide or any component of the preparation.
- You have significant kidney disease that has not been reviewed by your provider.
- You are pregnant or breastfeeding.
- You have Barth syndrome and are seeking FORZINITY or a substitute for the approved product.
- You are under 18.
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
SS-31, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Your provider evaluates SS-31 in the context of its mitochondrial inner-membrane and cardiolipin target rather than a generic “energy” claim.
- Kidney function, medications, medical history, and treatment goals are reviewed before prescribing.
- If approved, your dose and duration are set for you rather than left to guesswork.
- Your prescription is compounded by a licensed US pharmacy, with follow-up built into your care.
- Provider review, the prescription if approved, pharmacy, and shipping handled inside one plan.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Longevity.
BPC-157
The peptide everyone asks about, inside real medicine.
Compounded BPC-157 sourced through a licensed US pharmacy and placed inside clinician review, not a research-vendor checkout.
MOTS-c
A mitochondrial signal, not a stimulant.
A compounded mitochondrial-derived signaling peptide studied in cellular stress-response and AMPK-related metabolic biology.
Epithalon
The longevity peptide that rewards skepticism.
A compounded Epithalon prescription for the well-read patient who wants the molecule, evidence gaps, and sourcing stated plainly.
Serious risks
- The label also warns about serious hypersensitivity
- Longer exposure was associated with transient eosinophil elevations
- Elamipretide exposure rises with renal impairment, so kidney function matters
Commonly reported
- In its 12-patient placebo-controlled Barth syndrome trial, local administration reactions occurred in all 12 patients receiving FORZINITY
- Injection-site erythema occurred in all 12 and injection-site pain in 9
Because it is a compounded preparation
- May use a different concentration or inactive ingredients, which can change tolerability
Most human safety data come from FORZINITY, not the compounded preparation offered here. Human safety data for the use offered here are limited, so your provider reviews renal history, prior reactions, medications, and other risk factors before prescribing.
- FDA, FORZINITY (elamipretide) Prescribing Information, initial US approval September 2025.FDA
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
SS-31 is studied for interaction with cardiolipin, a phospholipid in the inner mitochondrial membrane. That makes the research thesis structural and membrane-specific rather than a general antioxidant claim. It does not establish a clinical outcome for the compounded preparation offered here.
Elamipretide is FDA-approved as FORZINITY to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. The preparation offered here is compounded for a different purpose and is not FORZINITY or a substitute for it. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.2
No. FORZINITY is a specific FDA-approved finished drug product containing elamipretide for a narrow Barth syndrome indication. The preparation offered here is compounded to an individual prescription for a different purpose. The active molecule may be the same, but the finished products are not interchangeable, and FORZINITY studies do not establish what this compounded preparation will do.
FORZINITY was evaluated in a 12-patient randomized, double-blind, placebo-controlled crossover trial in Barth syndrome. It was not superior to placebo on the primary six-minute-walk or fatigue endpoints. Increased knee extensor strength was observed during the extension period, and FDA used that intermediate endpoint for accelerated approval while requiring a confirmatory trial. Those findings belong to FORZINITY and its studied population, not this compounded preparation.2 Larger trials in primary mitochondrial myopathy also missed their primary endpoints.
SS-31 is the opposite of a molecule that benefits from vague marketing. It has a specific molecular target, an FDA-approved finished product with a narrow indication, negative trial results that matter, and a compounded preparation that is not interchangeable with that approved product. That is exactly the kind of record that deserves clinical interpretation. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. With AnthologyRX+, a licensed provider reviews the whole record and a licensed US pharmacy fills your individual prescription if treatment is appropriate. The sophistication is in knowing what the molecule is, what the evidence says, and what it does not let us claim.
- FDA, Drug Trials Snapshot: FORZINITY, September 19, 2025.FDA
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, and FDA Warning Letter to Gram Peptides, March 31, 2026.